Lactobacillus sakei to Treat Sinusitis - Quick Reference Sheet
evipedia.ai
← Back

Lactobacillus sakei to Treat Sinusitis

Created on 09/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Lactobacillus sakei, a food-fermenting bacterium, is sold as a nasal probiotic for long-lasting sinusitis. It is scarce in inflamed sinuses and helped in one mouse study; no human sinus result exists yet. Orally, it eased eczema in children and joint pain in adults, with short courses well tolerated; nothing is known about nasal use in people. Bloodstream infection from related bacteria occurred almost only in severely ill or immune-suppressed people. (Full Review)

Protocol

Registered trial regimen (topical)
proBio65 powder packet in 240 mL distilled or boiled water
Irrigated twice daily for 14 days; adults with surgically opened sinuses
Oral regimens from published trials
Roughly 1 × 10¹⁰ colony-forming units daily for 12 weeks
Used in other conditions; no oral regimen tested for sinus outcomes
Pre-existing conditions and response
Unoperated, obstructed sinuses limit irrigation access
Trial excluded cystic fibrosis, autoimmune sinonasal disease and immunocompromise
Time to effect
Eczema and knee osteoarthritis
12 weeks
Oral dosing; improvement measured at end of 12-week trials
Dry eye signs
4 weeks
Topical lysate eye drops; oral capsules produced no effect
Sinus symptoms
No controlled human data on onset
Registered trial measures at 2 and 6 weeks; user accounts describe changes within days

Benefits

Contraindications
  • Neutropenia (absolute neutrophil count <500/µL) or CD4 count <200 cells/µL
  • Solid organ or stem cell (bone marrow) transplant recipients on active immunosuppression
  • Indwelling central venous catheters, prosthetic heart valves, or prior infective endocarditis
  • Critical illness requiring intensive care, or active systemic infection
  • Cerebrospinal fluid leak, skull-base defect, or sinus surgery within the preceding 12 months
  • Short bowel syndrome or other severe intestinal barrier failure
  • Pregnancy and breastfeeding
    •
Key Interactions
  • Oral and topical antibiotics (amoxicillin-clavulanate, doxycycline, mupirocin, topical tobramycin irrigations)
  • Antiseptic and antibacterial nasal products (povidone-iodine rinses, baby shampoo irrigations, colloidal silver, xylitol at antibacterial concentrations)
  • Manuka honey and other antibacterial irrigation additives
  • Immunosuppressants (prednisone, tacrolimus) and biologics (rituximab, dupilumab)
  • Other probiotics and prebiotics (multi-strain oral products; inulin, fructo-oligosaccharides)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Invasive infection in immunocompromised or critically ill users; mild gastrointestinal and tolerability complaints with oral use; amoebic brain infection from contaminated irrigation water; local nasal irritation and nosebleed with intranasal use
    •
  • Speculative: Transfer of antibiotic resistance genes; delay of effective treatment for bacterial sinusitis
    •

Monitoring

Marker Target Why
SNOT-22 score <20; fall of ≥9 points = meaningful change Sinus symptom burden
Lund-Kennedy endoscopic score 0–2 (scale 0–20) Objective mucosal appearance
Endoscopically guided sinus culture No dominant pathogen Detects Staphylococcus aureus or Corynebacterium dominance
Absolute neutrophil count 1,800–7,000/µL Safety gate for invasive infection risk
Blood eosinophil count <200 cells/µL Separates polyp-associated, allergy-type disease that responds to other treatments
Serum total IgE <100 IU/mL Marks allergic subtype less likely to respond
High-sensitivity C-reactive protein <1.0 mg/L Rules out active infection before live-organism use
25-hydroxyvitamin D 40–60 ng/mL Low status associated with worse sinus disease

Cadence: Baseline symptom score, endoscopy, sinus culture, complete blood count with differential, inflammatory and allergy markers; symptom score at end of 2-week course and at 6 weeks, with endoscopy and repeat culture at 6 weeks; annual review where treatment is repeated

Qualitative Assessment

  • Nasal airflow and the ability to breathe through both nostrils overnight
  • Sense of smell
  • Facial pressure and headache frequency
  • Post-nasal discharge, its colour and volume
  • Number of antibiotic courses and days of missed work per year
  • Sleep quality and daytime energy
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.